...
artv-img

Artiva Biotherapeutics, Inc. Common Stock, Common Stock

ARTV

NMQ

$11.34

-$0.3

(-2.58%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$298.52M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.68 L
$17.31 H
$11.34

About Artiva Biotherapeutics, Inc. Common Stock, Common Stock

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameARTVSectorS&P500
1-Week Return-8.49%-3.13%-0.02%
1-Month Return-13%-4.8%1.48%
3-Month Return1.04%-8.46%9.63%
6-Month Return-3%-2.88%13.17%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue-2.00M4.93M33.49M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":5.98,"profit":true},{"date":"2022-12-31","value":14.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-2.00M4.93M33.49M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":5.98,"profit":true},{"date":"2022-12-31","value":14.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin-100.00%100.00%100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses18.27M55.27M64.76M64.16M[{"date":"2020-12-31","value":28.21,"profit":true},{"date":"2021-12-31","value":85.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.08,"profit":true}]
Operating Income(18.27M)(53.27M)(59.83M)(30.67M)[{"date":"2020-12-31","value":-1827100000,"profit":false},{"date":"2021-12-31","value":-5327200000,"profit":false},{"date":"2022-12-31","value":-5982900000,"profit":false},{"date":"2023-12-31","value":-3067100000,"profit":false}]
Total Non-Operating Income/Expense83.00K(18.55M)2.79M5.58M[{"date":"2020-12-31","value":1.49,"profit":true},{"date":"2021-12-31","value":-332.37,"profit":false},{"date":"2022-12-31","value":49.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(17.99M)(71.83M)(58.34M)(27.62M)[{"date":"2020-12-31","value":-1799100000,"profit":false},{"date":"2021-12-31","value":-7182500000,"profit":false},{"date":"2022-12-31","value":-5833500000,"profit":false},{"date":"2023-12-31","value":-2762400000,"profit":false}]
Income Taxes676.00K(18.55M)53.00K72.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2744.53,"profit":false},{"date":"2022-12-31","value":7.84,"profit":true},{"date":"2023-12-31","value":10.65,"profit":true}]
Income After Taxes(18.67M)(53.27M)(58.39M)(27.70M)[{"date":"2020-12-31","value":-1866700000,"profit":false},{"date":"2021-12-31","value":-5327200000,"profit":false},{"date":"2022-12-31","value":-5838800000,"profit":false},{"date":"2023-12-31","value":-2769600000,"profit":false}]
Income From Continuous Operations(17.99M)(71.83M)(58.39M)(27.70M)[{"date":"2020-12-31","value":-1799100000,"profit":false},{"date":"2021-12-31","value":-7182500000,"profit":false},{"date":"2022-12-31","value":-5838800000,"profit":false},{"date":"2023-12-31","value":-2769600000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(17.99M)(71.83M)(58.39M)(27.70M)[{"date":"2020-12-31","value":-1799100000,"profit":false},{"date":"2021-12-31","value":-7182500000,"profit":false},{"date":"2022-12-31","value":-5838800000,"profit":false},{"date":"2023-12-31","value":-2769600000,"profit":false}]
EPS (Diluted)----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARTV
Cash Ratio 11.03
Current Ratio 11.33

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARTV
ROA (LTM) 0.00%
ROE (LTM) -44.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARTV
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARTV
Trailing PE NM
Forward PE NM
P/S (TTM) 114.77
P/B 1.49
Price/FCF NM
EV/R 64.15
EV/Ebitda NM

FAQs

What is Artiva Biotherapeutics, Inc. Common Stock share price today?

Artiva Biotherapeutics, Inc. Common Stock (ARTV) share price today is $11.34

Can Indians buy Artiva Biotherapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Artiva Biotherapeutics, Inc. Common Stock (ARTV) on Vested. To buy Artiva Biotherapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARTV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Artiva Biotherapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Artiva Biotherapeutics, Inc. Common Stock (ARTV) via the Vested app. You can start investing in Artiva Biotherapeutics, Inc. Common Stock (ARTV) with a minimum investment of $1.

How to invest in Artiva Biotherapeutics, Inc. Common Stock shares from India?

You can invest in shares of Artiva Biotherapeutics, Inc. Common Stock (ARTV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARTV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Artiva Biotherapeutics, Inc. Common Stock shares
What is Artiva Biotherapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is $17.31. The 52-week low price of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is $9.68.

What is Artiva Biotherapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is

What is Artiva Biotherapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is 1.49

What is Artiva Biotherapeutics, Inc. Common Stock dividend yield?

The dividend yield of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is 0.00%

What is the Market Cap of Artiva Biotherapeutics, Inc. Common Stock?

The market capitalization of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is $298.52M

What is Artiva Biotherapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Artiva Biotherapeutics, Inc. Common Stock is ARTV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top